COMPANION IMMUNOSUPPRESSION WITH AZATHIOPRINE INCREASES THE FREQUENCY OF PERSISTENT RESPONSIVENESS TO PEGLOTICASE IN PATIENTS WITH CHRONIC REFRACTORY GOUT

被引：18
|
作者：
Rainey, H. [1 ]
Baraf, H. S. B. [2 ]
Yeo, A. [1 ]
Lipsky, P. [1 ]
机构：
[1] AMPEL BioSolut, Charlottesville, VA USA
[2] Ctr Rheumatol & Bone Res, Wheaton, IL USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.4642
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0410
引用
收藏
页码：438 / 439
页数：2
相关论文
共 50 条
  • [31] Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout
    Johnson, Richard J.
    Choi, Hyon K.
    Yeo, Anthony E.
    Lipsky, Peter E.
    HYPERTENSION, 2019, 74 (01) : 95 - 101
  • [32] Influence of Renal Function on the Velocity of Tophus Resolution and Achievement of Disease Remission in Patients with Chronic Refractory Gout Treated with Pegloticase
    Mandell, Brian F.
    Schlesinger, Naomi
    Edwards, N. Lawrence
    Yeo, Anthony
    Lipsky, Peter E.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [33] Clinical Efficacy Outcomes with up to 3 Years of Pegloticase Treatment for Refractory Chronic Gout.
    Becker, Michael A.
    Baraf, Herbert S. B.
    Yood, Robert A.
    Dillon, Aileen M.
    Vazquez-Mellado, Janitzia
    Ottery, Faith D.
    Khanna, Dinesh
    Sundy, John S.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S69 - S69
  • [34] ASSOCIATION OF RENAL DYSFUNCTION AND DEVELOPMENT OF TOPHI IN SUBJECTS WITH CHRONIC REFRACTORY GOUT AND RESPONSE TO TREATMENT WITH PEGLOTICASE
    Edwards, N. L.
    Singh, J.
    Troum, O.
    Yeo, A.
    Lipsky, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1049 - 1049
  • [35] Evaluation of the efficacy and safety of pegloticase for the treatment of chronic refractory gout through meta-analysis
    Fan, Tianci
    Wang, Yifan
    Song, Tongqing
    Sun, Yan
    INTRACTABLE & RARE DISEASES RESEARCH, 2023, 12 (02) : 114 - 117
  • [36] Pegloticase Provides Clinical Benefit in Patients with Chronic Refractory Gout Who Did Not Meet the Clinical Trial Biochemical Definition of Response
    Mandell, Brian F.
    Weisman, Michael
    Yeo, Anthony
    Lipsky, Peter E.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [37] Infusion-Related Reactions With Pegloticase, a Recombinant Uricase for the Treatment of Chronic Gout Refractory to Conventional Therapy
    Baraf, Herbert S. B.
    Yood, Robert A.
    Ottery, Faith D.
    Sundy, John S.
    Becker, Michael A.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2014, 20 (08) : 427 - 432
  • [38] Treatment with Pegloticase Significantly Decreases Mean Arterial Blood Pressure in Patients with Chronic Gout
    Choi, Hyon K.
    Johnson, Richard
    Yeo, Anthony
    Lipsky, Peter E.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [39] Pegloticase causes prolonged improvement in multiple disease parameters in patients with chronic refractory gout who maintain low serum urate levels
    Keenan, R. T.
    Yeo, A. E.
    Lipsky, P. E.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2022, 40 (05) : 1006 - 1010
  • [40] Target Tophus Size and Complete Response Rates In Patients Treated With Open-Label Pegloticase For Chronic Gout Refractory To Conventional Therapy
    Keenan, Robert T.
    Dalbeth, Nicola
    Baraf, Herbert S. B.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S505 - S505
12345